Randomized, open-label, multicenter study examining the effects of duration of treatment of PEGASYS [peginterferon alfa-2a] in combination with daily COPEGUS [ribavirin] + amantadine in patients with chronic HCV [hepatitis C virus] after relapse to previous (Peg)IFN [interferon] + ribavirin therapy.

Trial Profile

Randomized, open-label, multicenter study examining the effects of duration of treatment of PEGASYS [peginterferon alfa-2a] in combination with daily COPEGUS [ribavirin] + amantadine in patients with chronic HCV [hepatitis C virus] after relapse to previous (Peg)IFN [interferon] + ribavirin therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2011

At a glance

  • Drugs Amantadine (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms TRELA
  • Most Recent Events

    • 12 Jul 2011 Planned end date (Nov 2009) added as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-001207-19).
    • 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top